

Practitioner's Docket No. MPI98-047CP2DV1M

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:	Glucksmann, Maria A., et al.		
Application No.:	10/077,698	Group No.:	1646
Filed:	February 13, 2002	Examiner:	Brannock, Michael T.
For:	14273 RECEPTOR, A NOVEL G-PROTEIN COUPLED RECEPTOR		

Mail Stop Amendment

Confirmation No. 4059

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

TRANSMITTAL

1. Transmitted herewith for this application is/are:

- a. This Transmittal (3 pages);
- b. Amendment and Response under CFR §1.111 (26 pages);
- c. Transmittal of Supplemental Information Disclosure Statement (2 pages – in duplicate);
- d. Supplemental Information Disclosure Statement (2 pages);
- e. Form PTO/SB/08B (1 page);
- f. Copy of Reference cited in Information Disclosure Statement (Citation No. A12);
- g. Deposit Declaration (2 pages);
- h. Authorization to Act in a Representative Capacity (2 pages);
- i. Statement of Limited Recognition under 37CFR §11.9(b) for Mario Cloutier (1 page); and
- j. Return postcard.

STATUS

2. Applicant is other than a small entity.

CERTIFICATION UNDER 37 C.F.R. SECTIONS 1.8(a) and 1.10*

I hereby certify that, on the date shown below, this correspondence is being:

MAILING

deposited with the United States Postal Service in an envelope addressed to Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

37 C.F.R. SECTION 1.8(a)

37 C.F.R. SECTION 1.10*

with sufficient postage as first class mail.

as "Express Mail Post Office to Addressee"
Mailing Label No. _____

TRANSMISSION

transmitted by facsimile to the Patent and Trademark Office.



Signature

Sean Hunziker

(type or print name of person certifying)

Date: May 4, 2005

***WARNING:** Each paper or fee filed by "Express Mail" must have the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 C.F.R. section 1.10(b). "Since the filing of correspondence under section 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will not be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442.

PETITION FOR EXTENSION OF TIME

3. The proceedings herein are for a patent application and the provisions of 37 C.F.R. 1.136 apply.

Fee: \$0.00

Extension fee due with this request \$0.00

If an additional extension of time is required, please consider this a petition therefor.

FEE FOR CLAIMS

4. The fee for claims (37 C.F.R. 1.16(b)-(d)) has been calculated as shown below:

(Col. 1)	(Col. 2)	(Col. 3)	OTHER THAN A SMALL ENTITY
Claims Remaining After Amendment	Highest No. Previously Paid For	Present Extra	
Total 98	Minus 147	= 0	Rate \$50.00 = \$0.00
Indep. 14	Minus 21	= 0	\$200.00 = \$0.00
Multiple Dependent Claims	yes	yes	\$360.00 = \$0.00
		Total Addit. Fee	\$0.00
		Total additional fee for claims required	\$0.00

FEE PAYMENT

5. Charge Account No. 501668 the sum of \$0.00 (which includes the \$0.00 extension fee).


FEE DEFICIENCY

6. If any additional extension and/or fee is required, charge Account No. 501668.
If any additional fee for claims is required, charge Account No. 501668.

May 4, 2005

MILLENNIUM PHARMACEUTICALS, INC.

By *Mario Cloutier*
Mario Cloutier
Limited Recognition Under 37 C.F.R. §11.9(b)
40 Landsdowne Street
Cambridge, MA 02139
Telephone - 617-577-3522
Facsimile - 617-551-8820



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:	Glucksmann, Maria A., et al.		
Application No.:	10/077,698	Group No.:	1646
Filed:	February 13, 2002	Examiner:	Brannock, Michael T.
For:	14273 RECEPTOR, A NOVEL G-PROTEIN COUPLED RECEPTOR		

Mail Stop Amendment
 Commissioner for Patents
 P.O. Box 1450
 Alexandria, VA 22313-1450

DEPOSIT DECLARATION

Sir:

I, Mario Cloutier, hereby declare that:

1. I am the agent of record in the above-identified patent application.

CERTIFICATION UNDER 37 C.F.R. SECTIONS 1.8(a) and 1.10*

I hereby certify that, on the date shown below, this correspondence is being:

MAILING

deposited with the United States Postal Service in an envelope addressed to Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

37 C.F.R. SECTION 1.8(a) 37 C.F.R. SECTION 1.10*

with sufficient postage as first class mail. as "Express Mail Post Office to Addressee" Mailing Label No.

TRANSMISSION

transmitted by facsimile to the Patent and Trademark Office.

Signature

Sean Hunziker
 (type or print name of person certifying)

Date: May 4, 2005

*WARNING: Each paper or fee filed by "Express Mail" must have the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 C.F.R. section 1.10(b). "Since the filing of correspondence under section 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will not be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442.

2. *Escherichia coli* containing plasmid 14273, encoding human 14273 polypeptides described in the above-identified patent application, were deposited with the American Type Culture Collection (ATCC®), 10801 University Boulevard, Manassas, VA 20110-2209, on January 5, 2000 under the terms of the Budapest Treaty and assigned ATCC® Accession Number PTA-1143.

3. Upon granting of a patent on the above-identified patent application, all restrictions imposed by the depositor on the availability to the public of the deposited material will be irrevocably removed.

I hereby declare further that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further, that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the instant patent application or any patent issued thereon.

Respectfully submitted,

May 4, 2005

MILLENNIUM PHARMACEUTICALS, INC.

By



Mario Cloutier
Limited Recognition under 37 CFR §11.9(b)
40 Landsdowne Street
Cambridge, MA 02139
Telephone - 617-679-7336
Facsimile - 617-551-8820



Practitioner's Docket No. MPI98-047CP2DV1M

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:	Glucksmann, Maria A., et al		
Application No.:	10/077,698	Group No.:	1646
Filed:	February 13, 2002	Examiner:	Brannock, Michael T.
For:	14273 RECEPTOR, A NOVEL G-PROTEIN COUPLED RECEPTOR		

**Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450**

AUTHORIZATION TO ACT IN A REPRESENTATIVE CAPACITY

Dear Sir:

The practitioner named below is authorized to conduct interviews and has the authority to bind the principal concerned. Furthermore, the practitioner is authorized to file correspondence in the above-identified application pursuant to 37 CFR 1.34:

Mario Cloutier
Limited Recognition Under 37 CFR §11.9(b)
Customer Number 30405 or
Millennium Pharmaceuticals, Inc.
40 Lansdowne Street
Cambridge, MA 02139

CERTIFICATION UNDER 37 C.F.R. SECTIONS 1.8(a) and 1.10*

I hereby certify that, on the date shown below, this correspondence is being:

MAILING

deposited with the United States Postal Service in an envelope addressed to Mail Stop Amendment Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

37 C.F.R. SECTION 1.8(a)

37 C.F.R. SECTION 1.10*

with sufficient postage as first class mail.

as "Express Mail Post Office to Addressee" Mailing Label No.

TRANSMISSION

transmitted by facsimile to the Patent and Trademark Office.

Signature 

Sean Hunziker

Date: May 4, 2005

Sean Hunziker
(type or print name of person certifying)

***WARNING: Each paper or fee filed by "Express Mail" must have the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 C.F.R. section 1.10(b). "Since the filing of correspondence under section 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will not be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442.**

This is not a Power of Attorney to the above-named practitioner.

Accordingly, the practitioner named above does **not** have authority to sign a request to change the correspondence address, a request for an express abandonment, a disclaimer, a power of attorney, or other document requiring the signature of the applicant, assignee of the entire interest or an attorney of record. If appropriate, a separate Power of Attorney to the above-named practitioner should be executed and filed in the United States Patent and Trademark Office.

Please continue to forward all written and telephonic communications to Tracy M. Sioussat at the address and telephone number listed below.

SIGNATURE of Practitioner of Record

Respectfully submitted,

May 4, 2005

MILLENNIUM PHARMACEUTICALS, INC.

By Tracy M. Sioussat
Tracy M. Sioussat
Attorney/Agent for Applicant
Reg. No. 50,609
40 Landsdowne Street
Cambridge, MA 02139
Telephone: (617) 374-7679
Facsimile - (617) 551-8820



**BEFORE THE OFFICE OF ENROLLMENT AND DISCIPLINE
UNITED STATE PATENT AND TRADEMARK OFFICE**

LIMITED RECOGNITION UNDER 37 CFR § 11.9(b)

Mario Cloutier is hereby given limited recognition under 37 CFR 11.9(b) as an employee of Millenium Pharmaceuticals to prepare and prosecute patent applications wherein Millenium Pharmaceuticals is the assignee of record of the entire interest in the invention claimed in the application. This limited recognition shall expire on the date appearing below, or when whichever of the following events first occurs prior to the date appearing below: (i) Mario Cloutier ceases to lawfully reside in the United States, (ii) Mario Cloutier's employment with Millenium Pharmaceuticals ceases or is terminated, or (iii) Mario Cloutier ceases to remain or reside in the United States on an H-1 visa.

This document constitutes proof of such recognition. The original of this document is on file in the Office of Enrollment and Discipline of the U.S. Patent and Trademark Office.

Expires: December 29, 2006



Harry I. Moatz
Director of Enrollment and Discipline